Rohto Pharmaceutical ,Ltd. EBIT

The latest EBIT for RPHCF is $43B as of June 2026. That compares with $46B in the prior-year period — down 6.3% year over year. That is above the sector sector average of $-25M. Investors often review this figure alongside Rohto Pharmaceutical ,Ltd.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, RPHCF's EBIT moved from $46B to $43B — a 6.3% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Rohto Pharmaceutical ,Ltd.'s operating scale or balance-sheet position.

Against its sector companies, RPHCF currently prints $43B for EBIT, while the sector average sits near $-25M. That is roughly 169053.4% above the sector mean. Large gaps often invite a closer look at Rohto Pharmaceutical ,Ltd.'s growth, margins, and balance sheet.

A EBIT figure of $43B for RPHCF is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $-25M. Explore the charts below for those layers of context.

After noting RPHCF's EBIT ($43B), review year-over-year change from $46B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.